reference/31095685

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31095685

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	133
issn	0169-5002
pageRange	128-133
publicationName	Lung cancer (Amsterdam, Netherlands)
startingPage	128
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_68e48f72aa180752eb1096059a0f4bfb http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9269bca4efd63e2d2b202e18405f0691 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_2ac040078a95d2ca981f2f0ab15917fa
bibliographicCitation	Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing P, Zhang Z, Chuai S, Li J, Ying J. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer. 2018 Apr;118():128–33. doi: 10.1016/j.lungcan.2018.01.026. PMID: 29571990.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71782233fadc39ee1907716d4089ac9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6b809be0cd787d770387913f12003ae http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f09f885328abe6070bc994196dd741de http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_19b339dd9108dabacdef90405f26a978 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_776b94d840e8850bc847a0c2270c7cec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2febd6dbabe0218f487bcba9f45e97af http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b954baf86ee02fa23a94a70f1f89470 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec1d70480019572d01e3e9afad687ffb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b87e87b73fcbd18300fdd94f38c39730 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8652726324dbb0253eb35186e27a7050
date	201804
identifier	https://pubmed.ncbi.nlm.nih.gov/29571990 https://doi.org/10.1016/j.lungcan.2018.01.026
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8534 https://portal.issn.org/resource/ISSN/0169-5002
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants
discusses	http://id.nlm.nih.gov/mesh/M0024671 http://id.nlm.nih.gov/mesh/M0513130 http://id.nlm.nih.gov/mesh/M0228330 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0024670 http://id.nlm.nih.gov/mesh/M0553416 http://id.nlm.nih.gov/mesh/M0023875
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008175Q000235 http://id.nlm.nih.gov/mesh/D015514Q000235 http://id.nlm.nih.gov/mesh/D002289Q000235 http://id.nlm.nih.gov/mesh/D000077548Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D016159Q000235 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D059014 http://id.nlm.nih.gov/mesh/D011110 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008175Q000401 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D012189 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D002289Q000401 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D009154Q000235 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D000077547Q000627 http://id.nlm.nih.gov/mesh/D000970Q000627
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b23065537a07b03ba7e2ca1197841172 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_52a517e173e6fa70285ded085be0d86f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11626560

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID238

Total number of triples: 67.